Transcriptional regulation of programmed hypertension by melatonin: An epigenetic perspective

International Journal of Molecular Sciences

Volumn 15, Issue 10, 2014, Pages 18484-18495

  Tain, You Lin ^a   Huang, Li Tung ^a,b   Chan, Julie Y H ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Developmental programming; Epigenetic regulation; Hypertension; Melatonin; Next generation sequencing; Oxidative stress; Renin angiotensin system

Indexed keywords

DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; EPIDERMAL GROWTH FACTOR RECEPTOR; EPOXIDE HYDROLASE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; LYMPHOCYTE ANTIGEN; MELATONIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; RAS PROTEIN; SEMAPHORIN; TRANSCRIPTION FACTOR PAX2; TRANSFORMING GROWTH FACTOR BETA;

BLOOD PRESSURE MONITORING; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; FOCAL ADHESION; GENE EXPRESSION; HISTONE ACETYLATION; HUMAN; HYPERTENSION; INTRAUTERINE GROWTH RETARDATION; KIDNEY DEVELOPMENT; LOW BIRTH WEIGHT; NEXT GENERATION SEQUENCING; NONHUMAN; OXIDATIVE STRESS; PLEIOTROPY; PROGENY; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RNA INTERFERENCE; SEQUENCE ANALYSIS; SMALL CELL LUNG CANCER; TRANSCRIPTION REGULATION; TRYPTOPHAN METABOLISM; TUMOR GROWTH; UPREGULATION; WNT SIGNALING PATHWAY; ANIMAL; DRUG EFFECTS; EMBRYOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; KIDNEY; METABOLISM; PREGNANCY;

ANIMALS; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION; HUMANS; HYPERTENSION; KIDNEY; MELATONIN; PREGNANCY;

EID: 84907841531     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms151018484     Document Type: Review

References (36)

1. Luyckx, V. A.; Bertram, J. F.; Brenner, B. M.; Fall, C.; Hoy, W. E.; Ozanne, S. E.; Vikse, B. E. Effect of fetal and child health on kidney development and long-term risk of hypertension and kidney disease. Lancet 2013, 382, 273-283.
2. Ritz, E.; Amann, K.; Koleganova, N.; Benz, K. Prenatal programming-effects on blood pressure and renal function. Nat. Rev. Nephrol. 2011, 7, 137-144.
3. Tain, Y. L.; Hsieh, C. S.; Lin, I. C.; Chen, C. C.; Sheen, J. M.; Huang, L. T. Effects of maternal l-citrulline supplementation on renal function and blood pressure in offspring exposed to maternal caloric restriction: The impact of nitric oxide pathway. Nitric Oxide 2010, 23, 34-41.
4. Tain, Y. L.; Huang, L. T.; Hsu C. N.; Lee, C. T. Melatonin therapy prevents programmed hypertension and nitric oxide deficiency in offspring exposed to maternal caloric restriction. Oxid. Med. Cell. Longev. 2014, 2014, Article ID 283180.
5. Tain, Y. L.; Lee, W. C.; Hsu, C. N.; Lee, W. C.; Huang, L. T.; Lee, C. T.; Lin, C. Y. Asymmetric dimethylarginine is associated with developmental programming of adult kidney disease and hypertension in offspring of streptozotocin-treated mothers. PLoS One 2013, 8, e55420.
6. Tain, Y. L.; Leu, S.; Wu, K. L.; Lee, W. C.; Chan, J. Y. Melatonin prevents maternal fructose intake-induced programmed hypertension in the offspring: Roles of nitric oxide and arachidonic acid metabolites. J. Pineal Res. 2014, 57, 80-89.
7. Tain, Y. L.; Chen, C. C.; Sheen, J. M.; Yu, H. R.; Tiao, M. M.; Kuo, H. C.; Huang, L. T. Melatonin attenuates prenatal dexamethasone-induced blood pressure increase in a rat model. J. Am. Soc. Hypertens. 2014, 8, 216-226.
8. Tain, Y. L.; Sheen, J. M.; Chen, C. C.; Yu, H. R.; Tiao, M. M.; Kuo, H. C.; Huang, L. T. Maternal citrulline supplementation prevents prenatal dexamethasone-induced programmed hypertension. Free Radic. Res. 2014, 48, 580-586.
9. Paixão, A. D.; Alexander, B. T. How the kidney is impacted by the perinatal maternal environment to develop hypertension. Biol. Reprod. 2013, 89, 1-10.
10. Hardeland, R.; Tan, D. X.; Reiter, R. J. Kynuramines, metabolites of melatonin and other indoles: The resurrection of an almost forgotten class of biogenic amines. J. Pineal Res. 2009, 47, 109-126.
11. Hardeland, R.; Cardinali, D. P.; Srinivasan, V.; Spence, D. W.; Brown, G. M.; Pandi-Perumal, S. R. Melatonin-A pleiotropic, orchestrating regulator molecule. Prog. Neurobiol. 2011, 93, 350-384.
12. Tain, Y. L.; Huang, L. T.; Lin, I. C.; Lau, Y. T.; Lin, C. Y. Melatonin prevents hypertension and increased asymmetric dimethylarginine in young spontaneous hypertensive rats. J. Pineal Res. 2010, 49, 390-398.
13. Korkmaz, A.; Rosales-Corral, S.; Reiter, R. J. Gene regulation by melatonin linked to epigenetic phenomena. Gene 2012, 503, 1-11.
14. Chen, Y. C.; Sheen, J. M.; Tiao, M. M.; Tain, Y. L.; Huang, L. T. Roles of melatonin in fetal programming in compromised pregnancies. Int. J. Mol. Sci. 2013, 14, 5380-5401.
15. Burdge, G. C.; Hanson, M. A.; Slater-Jefferies, J. L.; Lillycrop, K. A. Epigenetic regulation of transcription: A mechanism for inducing variations in phenotype (fetal programming) by differences in nutrition during early life? Br. J. Nutr. 2007, 97, 1036-1046.
16. Bird, A. Perceptions of epigenetics. Nature 2007, 447, 396-398.
17. Korkmaz, A.; Reiter, R. J. Epigenetic regulation: A new research area for melatonin? J. Pineal Res. 2008, 44, 41-44.
18. Strakovsky, R. S.; Pan, Y. X. In utero oxidative stress epigenetically programs antioxidant defense capacity and adulthood diseases. Antioxid. Redox Signal. 2012, 17, 237-253.
19. Sharma, R.; Ottenhof, T.; Rzeczkowska, P. A.; Niles, L. P. Epigenetic targets for melatonin: Induction of histone H3 hyperacetylation and gene expression in C17. 2 neural stem cells. J. Pineal Res. 2008, 45, 277-284.
20. Jung-Hynes, B.; Reiter, R. J.; Ahmad, N. Sirtuins, melatonin and circadian rhythms: Building a bridge between aging and cancer. J. Pineal Res. 2010, 48, 9-19.
21. Wu, T. H.; Kuo, H. C.; Lin, I. C.; Chien, S. J.; Huang, L. T.; Tain, Y. L. Melatonin prevents neonatal dexamethasone induced programmed hypertension: Histone deacetylase inhibition. J. Steroid Biochem. Mol. Biol. 2014, 144, 253-259.
22. Ma, N.; Hardy, D. B. The fetal origins of the metabolic syndrome: Can we intervene? J. Pregnancy 2012, 2012, 482690.
23. Ferreira, D. S.; Amaral, F. G.; Mesquita, C. C.; Barbosa, A. P.; Lellis-Santos, C.; Turati, A. O.; Santos, L. R.; Sollon, C. S.; Gomes, P. R.; Faria, J. A.; et al. Maternal melatonin programs the daily pattern of energy metabolism in adult offspring. PLoS One 2012, 7, e38795.
24. Baxi, D. B.; Singh, P. K.; Vachhrajani, K. D.; Ramachandran, A, V. Neonatal corticosterone programs for thrifty phenotype adult diabetic manifestations and oxidative stress: Countering effect of melatonin as a deprogrammer. J. Matern. Fetal Neonatal Med. 2012, 25, 1574-1585.
25. Simko, F.; Paulis, L. Melatonin as a potential antihypertensive treatment. J. Pineal Res. 2007, 42, 319-322.
26. Rezzani, R.; Porteri, E.; de Ciuceis, C.; Bonomini, F.; Rodella, L. F.; Paiardi, S.; Boari, G. E.; Platto, C.; Pilu, A.; Avanzi, D.; et al. Effects of melatonin and Pycnogenol on small artery structure and function in spontaneously hypertensive rats. Hypertension 2010, 55, 1373-1380.
27. Agabiti-Rosei, C.; de Ciuceis, C.; Rossini, C.; Porteri, E.; Rodella, L. F.; Withers, S. B.; Heagerty, A. M.; Favero, G.; Agabiti-Rosei, E.; Rizzoni, D.; et al. Anticontractile activity of perivascular fat in obese mice and the effect of long-term treatment with melatonin. J. Hypertens. 2014, 32, 1264-1274.
28. Song, R.; van Buren, T.; Yosypiv, I. V. Histone deacetylases are critical regulators of the renin-angiotensin system during ureteric bud branching morphogenesis. Pediatr. Res. 2010, 67, 573-578.
29. Singh, H. J.; Keah, L. S.; Kumar, A.; Sirajudeen, K. N. S. Adverse effects of melatonin on rat pups of Wistar-Kyoto dams receiving melatonin supplementation during pregnancy. Exp. Toxicol. Pathol. 2012, 64, 751-752.
30. Vaiman, D.; Gascoin-Lachambre, G.; Boubred, F.; Mondon, F.; Feuerstein, J. M.; Ligi, I.; Grandvuillemin, I.; Barbaux, S.; Ghigo, E.; Achard, V.; et al. The intensity of IUGR-induced transcriptome deregulations is inversely correlated with the onset of organ function in a rat model. PLoS One 2011, 6, e21222.
31. Barker, D. J.; Osmond, C.; Golding, J.; Kuh, D.; Wadsworth, M. E. Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease. BMJ 1989, 298, 564-567.
32. Chong, E.; Yosypiv, I. V. Developmental programming of hypertension and kidney disease. Int. J. Nephrol. 2012, 2012, 760580.
33. Gitto, E.; Pellegrino, S.; Gitto, P.; Barberi, I.; Reiter, R. J. Oxidative stress of the newborn in the pre-and post-natal period and the clinical utility of melatonin. J. Pineal Res. 2009, 46, 128-139.
34. Grossman, E.; Laudon, M.; Yalcin, R.; Zengil, H.; Peleg, E.; Sharabi, Y.; Kamari, Y.; Shen-Orr, Z.; Zisapel, N. Melatonin reduces night blood pressure in patients with nocturnal hypertension. Am. J. Med. 2006, 119, 898-902.
35. Cagnacci, A.; Cannoletta, M.; Renzi, A.; Baldassari, F.; Arangino, S.; Volpe, A. Prolonged melatonin administration decreases nocturnal blood pressure in women. Am. J. Hypertens. 2005, 18, 1614-1618.
36. Scheer, F. A.; van Montfrans, G. A.; van Someren, E. J.; Mairuhu, G.; Buijs, R. M. Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension 2004, 43, 192-197.